Budget Amount *help |
¥14,820,000 (Direct Cost: ¥11,400,000、Indirect Cost: ¥3,420,000)
Fiscal Year 2016: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
Outline of Final Research Achievements |
A novel benzofuran compound 4-methoxybenzofuran-5-carboxamide (HMBC) was identified as an active ingredient from anti-allergic ayurvedic medicine Tephresia purpurea. MBCA suppressed H1 R gene expression through suppression of PKCd activation. In addition, MBCA isomer showed stronger H1R gene expression inhibitory activity than MBCA. In allergy model rats, it was found that MBCA ameliorates nasal symptoms through suppressing expression of H1R gene and Th2 cytokine gene such as IL-4, IL-5 of nasal mucosa. Furthermore, since MBCA suppresses IL-33 gene expression, it is suggested that not only acute symptoms of allergic rhinitis but also chronic symptoms may be improved by MBCA.
|